CRYOSITE LIMITED (CTE)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CTE - CRYOSITE LIMITED

FNArena Sector : Medical Equipment & Devices

Year End: June

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: 0.68

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$1.20 10 Mar 2026	0.000 OPEN $1.20	0.000 HIGH $1.20	0 LOW $1.20

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$1.20

10 Mar
2026

0.000

OPEN

$1.20

0.000

HIGH

$1.20

LOW

$1.20

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 16/03 - (franking Ex-Di

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2026 FactSet UK Limited. All rights reserved

Title	2020	2021	2022	2023	2024	2025
EPS Basic	xxx	xxx	xxx	xxx	xxx	3.9
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	14.1 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	4.9
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	2.2 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	13.35 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2020	2021	2022	2023	2024	2025
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	98.18 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	46.11 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	9.62 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	98.18 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	58.39 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	0.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2020	2021	2022	2023	2024	2025
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	0 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	2 M
Total Debt	xxx	xxx	xxx	xxx	xxx	2 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	5 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	15.22

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2020	2021	2022	2023	2024	2025
Capex	xxx	xxx	xxx	xxx	xxx	0.6 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	4.15 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	6 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	6 M
Research & Development	xxx	xxx	xxx	xxx	xxx	-
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Research as a Service (RaaS)	10/03/2026	-1	No Rating		-	Cryosite, which specialises in temperature-controlled storage and logistics for life sciences and pharmaceuticals businesses, showed an acceleration in growth in the first half. Revenue was up 24.6% and EBITDA up 32.5%. Research as a Service (RaaS) highlighted the Ultra-Frozen and Cryogenic segment, which posted 63.1% revenue growth. The acquisition of the new facility at Adderley Street West, Auburn has been completed and will provide critical capacity to meet growing demand. Research as a Service (RaaS) research doesn't carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Research as a Service (RaaS)

10/03/2026

-1

No Rating

Cryosite, which specialises in temperature-controlled storage and logistics for life sciences and pharmaceuticals businesses, showed an acceleration in growth in the first half. Revenue was up 24.6% and EBITDA up 32.5%.

Research as a Service (RaaS) highlighted the Ultra-Frozen and Cryogenic segment, which posted 63.1% revenue growth.

The acquisition of the new facility at Adderley Street West, Auburn has been completed and will provide critical capacity to meet growing demand.

Research as a Service (RaaS) research doesn't carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.

Access Extra Coverage Research History >

CTE STOCK CHART

FNArena News on CTE

Australian Broker Call Extra Edition – Mar 10, 2026

Mar 10 2026 - Daily Market Reports

Latest Medical Equipment & Devices News

1	GLP-1s Drive Strong Quarter For ResMed Feb 02 2026 - Australia

2	ImpediMed Ready To Scale Up Dec 16 2025 - Small Caps

3	Fisher & Paykel Healthcare’s Superior Profile Dec 02 2025 - Australia

4	4DMedical Poised For A Recovery Nov 25 2025 - Technicals

5	Treasure Chest: Pro Medicus Nov 12 2025 - Treasure Chest

6	Tariff Uncertainty Negates ResMed’s Q1 Positives Nov 05 2025 - Australia

7	Acquisition Loads Up Catapult Oct 20 2025 - Small Caps

8	Cochlear’s Future In Nexa’s Hands Aug 19 2025 - Australia

9	ResMed’s New Level Of Support Jul 29 2025 - Technicals

10	Strength To ‘AI’ Strength For Pro Medicus Jul 10 2025 - Australia

Get 2 Weeks free trial

Sign Up

Member Login

CRYOSITE LIMITED (CTE)
Share Price Analysis and Chart